0000000000515354
AUTHOR
Johannes Von Kempis
FRI0189 POOLED ANALYSIS OF THE REAL-WORLD EFFECTIVENESS OF BELIMUMAB IN TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS USING MULTI-COUNTRY DATA FROM THE OBSERVE STUDIES
Background: Real-world evidence of belimumab effectiveness in patients with systemic lupus erythematosus (SLE) has been reported separately for several countries through the OBSErve (evaluation Of use of Belimumab in clinical practice SEttings) programme. Objectives: To evaluate the effectiveness of belimumab in patients with SLE using pooled data from the individual OBSErve studies. Methods: This was a post hoc meta-analysis (GSK study 206351) of patient level data pooled from six retrospective observational cohort studies (Argentina, Canada, Germany, Spain, Switzerland, United States of America). Physicians provided data for adults (≥18 years; clinical diagnosis of SLE) who had initiated …
The combination of different antiphospholipid antibody subgroups in the sera of patients with autoimmune diseases is a strong predictor for thrombosis
Summary Objective: To determine the distribution of different antiphospholipid antibodies (APL-Ab) and their association with thrombosis in patients with autoimmune diseases. Methods: Clinical data and laboratory features of 30 patients with different autoimmune diseases with positive APL-Ab were retrospectively studied for a period of more than two years. Anti-cardiolipin (aCL), anti-phosphatidylserine (aPS) and anti-β2-glycoprotein I (aβ2-GPI) antibodies were determined by ELISA. Results: Autoantibodies that target only PS were detected in 53.3% (n=16) patients, aCL antibodies only were found in one patient (3,3%). In 43.3% (n=13), aPS were associated with elevated levels of aCL and/or aβ…